Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
21 October 2021 - 11:00PM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema (HAE), today announced that it will share new
preclinical results for STAR-0215 in a presentation titled
“STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein
Inhibitor for the Potential Treatment of HAE” at the 2021 American
College of Allergy, Asthma and Immunology Annual Scientific Meeting
in New Orleans, Louisiana.
The poster will be presented in-person by Andrew Nichols, Ph.D.,
Chief Scientific Officer at Astria Therapeutics, on Friday,
November 5, 2021 at 4:15pm CT, and will be available to all
registrants through the ACAAI Meeting website and mobile app.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in preclinical development for the
treatment of hereditary angioedema. Learn more about our company on
our website, www.astriatx.com, or follow us on Twitter and
Instagram @AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211021005224/en/
Astria Contacts:
Investor relations: Andrea
Matthews investors@astriatx.com
Media: Elizabeth Higgins media@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2023 to Apr 2024